🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Ramelteon

    Takeda

    Sleep Disorders, Circadian Rhythm

    phase 2 small molecule completed

    1 trial

  2. Ramelteon

    Takeda

    Migraine

    phase 2 small molecule terminated

    1 trial

  3. Ramelteon

    Takeda

    Sleep Disorder

    phase 2 small molecule completed

    1 trial

  4. Ramelteon and Placebo (25 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 2 small molecule completed

    1 trial

  5. Ramelteon and doxepin

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 2 small molecule completed

    1 trial

  6. Ramelteon and gabapentin

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 2 small molecule completed

    1 trial

  7. Ramelteon or Placebo

    Takeda

    Sleep Apnea, Obstructive

    phase 2 small molecule completed

    1 trial

  8. Ramelteon, triazolam, and placebo (56 possible combinations total)

    Takeda

    Drug Abuse

    phase 2 small molecule completed

    1 trial

  9. Recombinant human Arylsulfatase A (rhASA)

    Takeda

    Late Infantile Metachromatic Leukodystrophy

    phase 2 mab completed

    1 trial

  10. Recombinant human arylsulfatase A

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  11. Recombinant human heparan N-sulfatase (rhHNS)

    Takeda

    Mucopolysaccharidosis (MPS)

    phase 2 mab completed

    1 trial

  12. Recombinant human heparan N-sulfatase [rhHNS]

    Takeda

    Sanfilippo Syndrome

    phase 2 small molecule completed

    1 trial

  13. Recombinant human hyaluronidase + immune globulin intravenous

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 mab completed

    1 trial

  14. Relugolix

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  15. Replagal (agalsidase alfa)

    Takeda

    Fabry Disease

    phase 2 mab completed

    1 trial

  16. Roflumilast

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  17. Romidepsin

    Takeda

    Lymphoma, T-Cell, Peripheral

    phase 2 small molecule terminated

    1 trial

  18. SHP611

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

  19. SHP648

    Takeda

    Hemophilia B

    phase 2 gene therapy terminated

    1 trial

  20. SHP655

    Takeda

    Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

    phase 2 small molecule completed

    1 trial

  21. SM101

    Takeda

    Immunoglobulin A Nephropathy

    phase 2 mab terminated

    1 trial

  22. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  23. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  24. SPD489 20 mg

    Takeda

    Sleep Deprivation

    phase 2 small molecule completed

    1 trial

  25. SPD503 (Guanfacine HCl)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  26. SPD503 (extended-release Guanfacine hydrochloride)

    Takeda

    Generalized Anxiety Disorder (GAD)

    phase 2 small molecule completed

    1 trial

  27. SPD557

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule terminated

    1 trial

  28. SPD602

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  29. SPD602

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule terminated

    2 trials

  30. SPD602 (FBS0701, SSP-004184)

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule completed

    1 trial

  31. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  32. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  33. SSP-002358 (0.1 mg) + PPI

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  34. SSP-004184AQ

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  35. SYR-619

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  36. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  37. Soticlestat

    Takeda

    15q Duplication Syndrome

    phase 2 small molecule completed

    1 trial

  38. Soticlestat

    Takeda

    Complex Regional Pain Syndrome

    phase 2 small molecule completed

    1 trial

  39. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  40. Stem cells

    Takeda

    Rheumatoid Arthritis Aggravated

    phase 2 gene therapy completed

    1 trial

  41. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  42. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  43. TAK-018

    Takeda

    Crohn Disease

    phase 2 small molecule terminated

    1 trial

  44. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  45. TAK-062

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  46. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  47. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  48. TAK-079

    Takeda

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.